Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES DUSTIN AND ALTOR IN CONNECTION WITH THE LISTING ON NASDAQ STOCKHOLM
Mandate

VINGE ADVISES DUSTIN AND ALTOR IN CONNECTION WITH THE LISTING ON NASDAQ STOCKHOLM

February 17, 2015

Vinge advises Dustin Group AB (publ) and Altor in connection with Dustin’s listing on Nasdaq Stockholm.

Dustin is a leading online based reseller of IT products and services in the Nordics. Dustin offers a wide product and service range to businesses, public organisations and consumers, primarily through its online platform. The Swedish language prospectus was published on 2 February 2015 and the first day of trading was 13 February 2015. The offering price has been set at SEK 50 per share, corresponding to a market value of Dustin of approximately SEK 3,809 million.
Vinge’s team primarily consisted of Peter Bäärnhielm, David Andersson, Sabina Börjesson, Amanda Knutsson and Tora Hansjons.

Vinge företräder Dustin och Altor i samband med börsnoteringen på Nasdaq Stockholm

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025